Combination Therapy with Sunitinib and Gemcitabine in Rapidly Progressive mRCC

Standard single-agent treatment options offer meager prospects for metastatic sarcomatoid renal cell carcinoma (RCC) and poor-risk RCC, both of which demonstrate aggressive tumor biology and rapid clinical disease progression. However, results of a single-arm, open-label, phase II trial suggest that combining select treatment options may deliver the necessary punch to keep these aggressive forms of RCC in check (Abstract 408).03/01/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news